Work

Safety and efficacy of QLC5508 (MHB088C) in heavily-treated patients with metastatic castration-resistant prostate cancer: Updated data from a phase 1/2 trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5046

Authors: Xinan Sheng, Yuping Sun, Xue Meng, Yanqiu Zhao, Hai Huang, Liang Han, Zhen Zhang, Qi Ma, Feng Chang, Yinghua Ji, Ou Jiang, Fangling Ning, Guoqing Cao, Jun Hu, Hongying Wei, Tao Zhang, Xiaoyan Kang, Jun Guo, Lin Shen

Institutions: Peking University Cancer Hospital, Shandong First Medical University, Shandong Tumor Hospital, Henan Cancer Hospital, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Xuzhou Central Hospital, Ningbo University, Ningbo University Affiliated Hospital, Changzhi Medical College, First Affiliated Hospital of Xinxiang Medical University, Binzhou Medical University, Qilu Pharmaceutical Co., Ltd. (China)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162507010

Cites:

Cited by: 1

Related to: